Immunicum to Participate in Upcoming Conferences

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming conferences:

Kempen’s 14th Life Sciences Conference in Amsterdam

April 20-21, 2022

Immunicum CEO Erik Manting will present on Thursday, April 21, at 1:30 pm CET.

https://www.kempen.com/en/securities/events/life-sciences-conference

10th CCBIO Annual Symposium

May 10-11, 2022

www.ccbiosymposium.no

19TH CIMT Annual Meeting

May 10-12, 2022

https://www.meeting.cimt.eu/

 

FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@immunicum.com

 

INVESTOR RELATIONS

Brendan Payne

Stern Investor Relations

Telephone: +1 212-698-8695

E-mail: brendan.payne@sternir.com

 

MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu

 

ABOUT IMMUNICUM AB (PUBL)

Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

 

Attachment

Keep reading

Immunicum AB (publ) Publishes the Annual Report for 2021